Treatment of adult patients with immune thrombocytopenia after failure of first-line therapies

Record ID 32018002264
Authors' objectives: CADTH will undertake a Health Technology Assessment to review the effectiveness and cost-effectiveness of treatments for ITP in adults after failure of first-line treatments. A secondary objective will be to determine the place in therapy of splenectomy.
Project Status: Ongoing
Anticipated Publish Date: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
MeSH Terms
  • Thrombocytopenia
  • Adult
  • Purpura, Thrombocytopenic, Idiopathic
  • Drug Therapy
  • Immunoglobulins
  • Immunoglobulins, Intravenous
  • Immune thrombocytopenia
  • Intravenous immunoglobulins
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.